Boehringer Ingelheim taps a popular antibody discovery player for access to drug 'library of libraries'
Over the past two years, Twist Bioscience — one of the most relied upon companies in biotech and academia for its DNA synthesis services — has been shifting into therapeutics, striking dozens of deals with pharma companies for access to its antibody “library of libraries.”
But none so far can match the deal they’ve just inked with Boehringer Ingelheim.
Boehringer will dole out up to $710 million in milestones to use Twist’s libraries to discover antibodies against a broad range of undisclosed targets, the companies announced on Thursday. The pharma giant will also pay an undisclosed upfront fee for each program that takes off.
Keep reading Endpoints with a free subscription
Unlock this story instantly and join 118,600+ biopharma pros reading Endpoints daily — and it's free.